SEC Filing Summary

Robinson Chandler, Chief Executive Officer of Monopar Therapeutics, reported a transaction on 2026-10-20 involving 597 shares of Common Stock acquired at a price of $92.59 per share. This transaction, coded as "D", resulted in a post-transaction share count of 104,127. Additionally, Mr. Chandler holds 62,815 shares indirectly, as indicated by footnote F2, which refers to shares held by the Chandler D. Robinson Irrevocable Trust. Footnote F1 clarifies that the 597 shares withheld were to cover taxes due to an administrative error related to restricted stock units vesting.